Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)
Survival rates for childhood ALL have improved dramatically in recent decades, with 5‑year survival increasing from 60 % to nearly 90 % in children younger than 15 years and from 28 % to over 75 % in adolescents aged 15–19 years.
This National Cancer Institute PDQ® (Professional Version) review summarizes the epidemiology, risk factors, genetics, diagnosis, treatment, and outcomes of childhood acute lymphoblastic leukemia (ALL). It highlights the dramatic improvement in survival over the past five decades, the diverse genetic and environmental risk factors, and the importance of ongoing clinical trials. The review also discusses late effects and the need for long‑term monitoring of survivors.
Understanding the remarkable advances in childhood ALL survival underscores the successes of modern therapy while simultaneously drawing attention to lingering issues such as late‑effects and the need for continued research. Long‑term monitoring and risk‑adapted therapy are essential to maintain these gains and improve quality of life for survivors.
Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Kapcsolódó jelek
- Acute Myeloid Leukemia Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf
- Recent advances on blinatumomab for acute lymphoblastic leukemia
- NCT05800210: Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Acute Lymphoblastic Leukemia
- Advancing the Diagnosis of Non‑Hodgkin Lymphoma Through Next‑Generation Sequencing in Developing Countries: An Evaluation of Progress — A Narrative Review
- The Evolving Therapeutic Revolution in Adult Acute Lymphoblastic Leukemia